Company: Buck Institute on Aging
Job title: Professor & Vice President, Academic Affairs
A native of Scotland, Dr. Lithgow received his PhD from the University of Glasgow and obtained further training at Ciba Geigy AG in Basel, Switzerland, and at the University of Colorado. He established his lab studying the biology of aging at the University of Manchester, England, before moving it to the Buck Institute in 2000.
Dr. Lithgow has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging, a senior scholarship from the Ellison Medical Foundation, and the Tenovus Award for Biomedical Research. He is also the 2019 Denham Harman Award Winner, an award made by the American Aging Association for significant contributions to aging research. He has served on many national advisory panels in both the United Kingdom and the United States, including the National Institute on Aging’s Board of Scientific Councilors, and has served as the Chair of Biological Sciences at the Gerontology Society of America.
Dr. Lithgow has partnered with a series of biotechnology companies in sponsored research agreements and has strong collaborations in preclinical aging research on diseases such as osteoporosis and Parkinson’s disease. He is also a co-founder of Gerostate Alpha, a startup pharmaceutical company focused on aging. The Lithgow lab concentrates on identifying small drug-like molecules that re-engage and enhance homeostatic mechanisms in the microscopic nematode worm C. elegans. They aim to boost mechanisms that prevent protein misfolding and remove damaged proteins and other forms of molecular damage. Frequently, treatment with such molecules results in lifespan extension and postpones disease pathology. They now collaborate with other Buck researchers to test the effectiveness of these compounds to prevent chronic disease in mouse models.
Panel Discussion: A Therapeutic Revolution Against Aging – Bridging the Gaps & Opportunities 4:50 pm
Examining what we do and do not know about the aging process Exploring the targeting of aging as a disease vs. aging as a common factor for different conditions Analyzing the current R&D landscape for anti-aging therapeutics Discussing recent breakthroughs and the growing interest in this space – attracting funding/ partnerships, important learnings to date…Read more
day: Day One
An Aging Intervention that Increases Lifespan & Compresses Morbidity 12:05 pm
Is it trivial to find small molecule interventions in aging (in simple laboratory animals)? Explore how health span increase is also attainable Examine how extension of mouse lifespan and health span has been demonstratedRead more
day: Day One